0000899243-21-013283.txt : 20210324 0000899243-21-013283.hdr.sgml : 20210324 20210324160514 ACCESSION NUMBER: 0000899243-21-013283 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210322 FILED AS OF DATE: 20210324 DATE AS OF CHANGE: 20210324 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pons Jaume CENTRAL INDEX KEY: 0001816977 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39386 FILM NUMBER: 21768261 MAIL ADDRESS: STREET 1: C/O ALX ONCOLOGY HOLDINGS INC. STREET 2: 866 MALCOLM ROAD, SUITE 100 CITY: BURLINGAME STATE: CA ZIP: 94010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALX ONCOLOGY HOLDINGS INC CENTRAL INDEX KEY: 0001810182 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 850642577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 866 MALCOLM ROAD, SUITE 100 CITY: BURLINGAME STATE: CA ZIP: 94010 BUSINESS PHONE: 650-466-7125 MAIL ADDRESS: STREET 1: 866 MALCOLM ROAD, SUITE 100 CITY: BURLINGAME STATE: CA ZIP: 94010 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-22 0 0001810182 ALX ONCOLOGY HOLDINGS INC ALXO 0001816977 Pons Jaume C/O ALX ONCOLOGY HOLDINGS INC. 866 MALCOLM ROAD, SUITE 100 BURLINGAME CA 94010 1 1 0 0 President and CEO Common Stock 2021-03-22 4 M 0 16700 1.91 A 568046 D Common Stock 2021-03-22 4 S 0 1200 63.7875 D 566846 D Common Stock 2021-03-22 4 S 0 900 64.9846 D 565946 D Common Stock 2021-03-22 4 S 0 600 66.325 D 565346 D Common Stock 2021-03-22 4 S 0 1500 67.1823 D 563846 D Common Stock 2021-03-22 4 S 0 2700 68.27 D 561146 D Common Stock 2021-03-22 4 S 0 9200 69.7671 D 551946 D Common Stock 2021-03-22 4 S 0 600 70.1243 D 551346 D Employee Stock Option (right to buy) 1.91 2021-03-22 4 M 0 16700 0.00 D 2029-09-12 Common Stock 16700 89019 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.33 to $64.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.64 to $65.25, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.80 to $66.69, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.81 to $67.79, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.81 to $68.80, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.97 to $69.95, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.20, inclusive. The option is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on June 16, 2019. /s/ Peter Garcia, by power of attorney 2021-03-24